Skip to Content
Search Menu

ASCO GU 2026: Enzalutamide + Radium-223 Improve Survival in mCRPC

At ASCO GU 2026, Enrique Gallardo, MD, Consultant, Parc Taulí University Hospital, Barcelona, Spain, presented the final overall survival results from the EORTC 1333/PEACE-3 trial. In this MEDtalk, he explains why the combination of enzalutamide with radium-223 is a valid option for patients with metastatic castration-resistant prostate cancer.
Enrique Gallardo

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

ASCO GU 2026: Adjuvant Belzutifan + Pembrolizumab Reduces Risk of Recurrence or Death in ccRCC

/ Jan Andreasen
ASCOGU26
Martin Zarba

RWD for mRCC: Cabozantinib + Nivolumab Shows Comparable Results to CheckMate 9ER

/ Martin Zarba
ASCOGU26Kidney cancer Play the Video 6:11
Fernando De Moura

ASCO GU 2026: Intensifying Neoadjuvant Androgen Blockade Before Prostatectomy in High-Risk Prostate Cancer

/ Fernando de Moura
ASCOGU26Prostate cancer Play the Video 4:11

Sustained efficacy and quality of life with darolutamide + ADT in mHSPC patients of all ages

/ Jan Andreasen
ESMO25Prostate cancer

ESMO 2025: Darolutamide-Treated mHSPC Patients Show a More Durable and Stronger PSA Response vs Abiraterone 

/ Alicia Morgans / Amanda Feldballe Bernholm
ESMO25Prostate cancer
Neeraj Agarwal

Talazoparib and Enzalutamide: A Game-Changer for mCRPC

/ Neeraj Agarwal
ASCOGU25Prostate cancer Play the Video 18:34

Bone Pain as a Key Prognostic Indicator in Castration-Sensitive Prostate Cancer

/ Deniz Tural / Jan Andreasen
ASCOGU25Prostate cancer
Nick James

Oestrogen Reimagined: A Breakthrough Approach for Metastatic Prostate Cancer

/ Nick James
ASCOGU25Prostate cancer Play the Video 09:06

Norwegian Perspectives on Urogenital Cancer at ESMO 2024

/ BestPractice Nordic
Bladder cancerESMO24Kidney cancerProstate cancer
Back to top